BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8232489)

  • 1. Control of chemotherapy-induced emesis.
    Grunberg SM; Hesketh PJ
    N Engl J Med; 1993 Dec; 329(24):1790-6. PubMed ID: 8232489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The control of chemotherapy-induced nausea and vomiting].
    Shinkai T; Saijo N; Sawamura N; Funaki U; Takahashi S; Yokoyama S; Fujita J; Futami H; Sasaki Y; Shimizu E
    Gan No Rinsho; 1985 Jun; 31(7):779-91. PubMed ID: 3897622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
    Herrstedt J
    Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recent advances in the management of chemotherapy-induced emesis].
    Murakami M; Ota K
    Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):401-11. PubMed ID: 3006594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods.
    Mahesh R; Perumal RV; Pandi PV
    Pharmazie; 2005 Feb; 60(2):83-96. PubMed ID: 15739895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiemetics: an update and the MASCC guidelines applied in clinical practice.
    Herrstedt J
    Nat Clin Pract Oncol; 2008 Jan; 5(1):32-43. PubMed ID: 18097455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of serotonin antagonists for the control of chemotherapy-induced emesis.
    Hainsworth JD
    Semin Surg Oncol; 1993; 9(3):279-84. PubMed ID: 8516617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of vomiting associated with cytotoxic therapy.
    Jones AL; Cunningham D
    Br J Hosp Med; 1991 Feb; 45(2):85-8. PubMed ID: 2018889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of chemotherapy-induced nausea and vomiting.
    Tortorice PV; O'Connell MB
    Pharmacotherapy; 1990; 10(2):129-45. PubMed ID: 2190193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-emetic therapy in cancer chemotherapy: current status.
    Herrstedt J; Dombernowsky P
    Basic Clin Pharmacol Toxicol; 2007 Sep; 101(3):143-50. PubMed ID: 17697032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of nausea and vomiting caused by anticancer drugs: state of the art.
    Pisters KM; Kris MG
    Oncology (Williston Park); 1992 Feb; 6(2 Suppl):99-104. PubMed ID: 1532744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy.
    Decker GM; DeMeyer ES; Kisko DL
    J Support Oncol; 2006 Jan; 4(1):35-41, 52. PubMed ID: 16444851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and cost effectiveness of new antiemetic guidelines.
    Engstrom C; Hernandez I; Haywood J; Lilenbaum R
    Oncol Nurs Forum; 1999 Oct; 26(9):1453-8. PubMed ID: 11064877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy-induced nausea and vomiting: state of the art in 2006.
    Schwartzberg L
    J Support Oncol; 2006 Feb; 4(2 Suppl 1):3-8. PubMed ID: 16499138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.
    Navari RM; Reinhardt RR; Gralla RJ; Kris MG; Hesketh PJ; Khojasteh A; Kindler H; Grote TH; Pendergrass K; Grunberg SM; Carides AD; Gertz BJ
    N Engl J Med; 1999 Jan; 340(3):190-5. PubMed ID: 9917226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
    Bruntsch U; Drechsler S; Eggert J; Gosse H; Ukena D; Imhoff W; Faerber L
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):7-11. PubMed ID: 9113120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy.
    Doherty KM
    Clin J Oncol Nurs; 1999 Jul; 3(3):113-9. PubMed ID: 10690042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.